A type of drug-resistant tuberculosis that is resistant to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to resistance...
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 16, 2026
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning extensively drug-resistant tuberculosis
Updated Jan 19, 2017
A study published in The New England Journal of Medicine reveals that extensively drug-resistant tuberculosis (XDR TB) is transmitted from person to person in KwaZulu-Natal, South Africa, during 2011-2014. This finding underscores the urgent need for enhanced public health strategies to combat the spread of XDR TB.
The CDC updates on its investigation into a case of extensively drug-resistant tuberculosis (XDR TB), advising potential exposure notifications for passengers and crew on two trans-Atlantic flights. This public health action highlights the ongoing challenges in managing XDR TB outbreaks.
The CDC is conducting a public health investigation to identify individuals exposed to a person infected with extensively drug-resistant tuberculosis (XDR-TB). This briefing highlights the urgency of the situation and the need for community awareness.